Skip to main content

Stimate® Nasal Spray National Drug Shortage

Last updated on

The Texas Health and Human Services Commission (HHSC) was made aware that Ferring Pharmaceuticals has issued a voluntary recall for all batches of its product called Stimate® (desmopressin acetate) Nasal Spray, 1.5mg/ml. The product is currently on the U.S. Federal Drug Administration national drug shortage list, and the manufacturer estimates that Stimate® will not become available until the second half of 2023.

The Medicaid and Children's Health Insurance Program (CHIP) formularies include several alternative desmopressin products prescribing providers may consider for compounding given the ongoing shortage of Stimate®. The National Drug Codes (NDCs) for desmopressin are below, and Medicaid-enrolled prescribers may consider these for compounding a nasal spray with a valid prescription.

Drug name

Strength

NDC

DESMOPRESSIN VIAL

4 MCG/ML

00703505103

DESMOPRESSIN VIAL

4 MCG/ML

00703505401

DESMOPRESSIN VIAL

40 MCG/10 ML

16714001501

DESMOPRESSIN VIAL

4 MCG/ML

69918090110

DESMOPRESSIN AMPULE

4 MCG/ML

43598093109

DESMOPRESSIN AMPULE

4 MCG/ML

43598093111

DESMOPRESSIN AMPULE

4 MCG/ML

69918089910

Prescribers may reach out to local compounding pharmacies for further guidance and assistance related to prescriptions for a compounded formulation of desmopressin nasal spray.

Email VDP-Formulary@hhsc.state.tx.us with questions or comments.